Cidara CEO Stein brings Trius gang, biotech vets together
This article was originally published in Scrip
Executive Summary
Everyone wondering what Jeffrey Stein would do next after Cubist Pharmaceuticals acquired Trius Therapeutics has their answer: The former Trius president and CEO will lead the antifungal startup Cidara Therapeutics and bring colleagues from his prior post and other local companies to the new venture.
You may also be interested in...
Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications
Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.
Agenovir: Using Gene Editing To Kill Viral DNA
Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.